Aligning Artificial Intelligence and Laboratory Execution in Drug Discovery
From In Silico Design to In Vitro Impact
Yann Gaston-Mathé, Iktos

Artificial intelligence is transforming molecular design, but synthesis remains the limiting step in drug discovery. To translate computational advances into real productivity gains, organizations must better align digital design with laboratory execution. AI-driven orchestration provides a practical framework to coordinate design, synthesis, and testing within existing R&D infrastructures, accelerating the transition from in silico hypotheses to in vitro validation and improving the productivity of the DMTA cycle.
The Acceleration Paradox
Artificial intelligence is reshaping how molecules are conceived. Generative models can now explore vast regions of chemical space, proposing and optimizing candidate structures with unprecedented speed.
Continue with login
No account yet?
Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.
Registermost read

Lead or Lag: Europe’s AI Materials Race
How AI and Robotics are reshaping the race for materials discovery.

Pharma 4.0 – the Key Enabler for Successful Digital Transformation in Pharma
Part 1: Building a Business Case for Pharma 4.0

Q1 2025 Chemical Industry: Diverging Trends
The first quarter of 2025 highlights a continued divergence between the European and US chemical industries.

20 Years of CHEManager International
Incredible but true: CHEManager International is celebrating its 20th anniversary!

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance
The ECA Foundation, one of the most important not-for-profit organizations for regulatory expertise in the pharmaceutical industry, aims to become the largest independent GMP/GDP organization in the world.











